SM 04554

Drug Profile

SM 04554

Alternative Names: SM-04554

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Samumed
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia

Most Recent Events

  • 21 Mar 2017 Clinical development is ongoing in USA and Australia (Topical)
  • 06 Mar 2017 Efficacy and adverse event data from a phase II trial in presented at the 75th American Academy of Dermatology (AAD-2017)
  • 01 Apr 2016 Samumed completes a phase II trial for Alopecia in USA (NCT02503137)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top